Moyamoya disease (MMD) is closely associated with the Ring Finger Protein 213 (RNF213), a susceptibility gene for MMD. However, its biological function remains unclear. We aimed to elucidate the role of RNF213 in the damage incurred by human endothelial cells under oxygen-glucose deprivation (OGD). We analyzed autophagy in peripheral blood mononuclear cells (PBMCs) derived from patients carrying either RNF213 wildtype (WT) or variant (p.R4810K). Subsequently, human umbilical vein endothelial cells (HUVECs) were transfected with RNF213 WT (HUVECWT) or p.R4810K (HUVECR4810K) and exposed to OGD for 2 h. Immunoblotting was used to analyze autophagy marker proteins, and endothelial function was analyzed by tube formation assay. Autophagic vesicles were observed using transmission electron microscopy. Post-OGD exposure, we administered rapamycin and cilostazol as potential autophagy inducers. The RNF213 variant group during post-OGD exposure (vs. pre-OGD) showed autophagy inhibition, increased protein expression of SQSTM1/p62 (p < 0.0001) and LC3-II (p = 0.0039), and impaired endothelial function (p = 0.0252). HUVECR4810K during post-OGD exposure (versus pre-OGD) showed a remarkable increase in autophagic vesicles. Administration of rapamycin and cilostazol notably restored the function of HUVECR4810K and autophagy. Our findings support the pivotal role of autophagy impaired by the RNF213 variant in MMD-induced endothelial cell dysfunction.
KurodaSHoukinK.Moyamoya disease: current concepts and future perspectives. Lancet Neurol2008;
7: 1056–1066.
2.
KamadaFAokiYNarisawaA, et al.
A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet2011;
56: 34–40.
3.
BangOYChungJWKimSJ, et al.
Caveolin-1, ring finger protein 213, and endothelial function in moyamoya disease. Int J Stroke2016;
11: 999–1008.
4.
NarducciAYasuyukiKOnkenJ, et al.
In vivo demonstration of blood-brain barrier impairment in moyamoya disease. Acta Neurochir (Wien)2019;
161: 371–378.
5.
MiyoshiKChidaKKobayashiM, et al.
Two-Year clinical, cerebral hemodynamic, and cognitive outcomes of adult patients undergoing medication alone for symptomatically ischemic moyamoya disease without cerebral misery perfusion: a prospective cohort study. Neurosurgery2019;
84: 1233–1241.
6.
Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of willis). Neurol Med Chir (Tokyo)2012;
52: 245–266.
7.
AbediASizdahkhaniSChoiW, et al.
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions. Neurosurg Focus2023;
55: E9.
8.
SeoWKKimJYChoiEH, et al.
Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study. J Am Heart Assoc2021;
10: e017701.
9.
HuangYChengYWuJ, et al.
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol2008;
7: 494–499.
10.
NakamuraTTsurutaSUchiyamaS.Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci2012;
313: 22–26.
11.
LeeSJLeeJSChoiMH, et al.
Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. BMC Neurol2017;
17: 169.
12.
BurkeGMBurkeAMShermaAK, et al.
Moyamoya disease: a summary. Neurosurg Focus2009;
26: E11.
13.
MalekAMConnorsSRobertsonRL, et al.
Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and Central nervous system disorders. Pediatr Neurosurg1997;
27: 182–189.
14.
LiuWMoritoDTakashimaS, et al.
Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One2011;
6: e2254220110720.
15.
OhkuboKSakaiYInoueH, et al.
Moyamoya disease susceptibility gene RNF213 links inflammatory and angiogenic signals in endothelial cells. Sci Rep2015;
5: 13191.
16.
HitomiTHabuTKobayashiH, et al.
Downregulation of securin by the variant RNF213 R4810K (rs112735431, G > A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients. Biochem Biophys Res Commun2013;
438: 13–19.
17.
CecchiACGuoDRenZ, et al.
RNF213 rare variants in an ethnically diverse population with moyamoya disease. Stroke2014;
45: 3200–3207.
18.
MotekiYOndaHKasuyaH, et al.
Systematic validation of RNF213 coding variants in Japanese patients with moyamoya disease. J Am Heart Assoc2015;
4: 20150511.
19.
ChongPFOgataRKobayashiH, et al.
Early onset of moyamoya syndrome in a down syndrome patient with the genetic variant RNF213 p.R4810K. Brain Dev2015;
37: 822–824.
20.
KamimuraTOkazakiSMorimotoT, et al.
Prevalence of RNF213 p.R4810K variant in early-onset stroke with intracranial arterial stenosis. Stroke2019;
50: 1561–1563.
21.
WangYZhangZWeiL, et al.
Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of chinese moyamoya disease. Neurology2020;
94: e678–e686.
22.
MiyatakeSMiyakeNTouhoH, et al.
Homozygous c.14576G > a variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology2012;
78: 803–810.
23.
AhelJLehnerAVogelA, et al.
Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. Elife2020;
9: 20200623.
24.
BhardwajABanhRSZhangW, et al.
MMD-associated RNF213 SNPs encode dominant-negative alleles that globally impair ubiquitylation. Life Sci Alliance2022;
5: 20220208.
25.
DasGShravageBVBaehreckeEH.Regulation and function of autophagy during cell survival and cell death. Cold Spring Harb Perspect Biol2012;
4: 20120601.
26.
EsclatineAChaumorcelMCodognoP.Macroautophagy signaling and regulation. Curr Top Microbiol Immunol2009;
335: 33–70.
27.
ChenZWuXZhouD, et al.
Characteristics of cerebral ischemic stroke based on moyamoya disease and atherosclerosis-associated intracranial arterial stenosis. Neurol Sci2022;
43: 1087–1096.
28.
UeharaTBangOYKimJS, et al.
Risk factors. Front Neurol Neurosci2016;
40: 47–57.
29.
FettermanJLHolbrookMFlintN, et al.
Restoration of autophagy in endothelial cells from patients with diabetes mellitus improves nitric oxide signaling. Atherosclerosis2016;
247: 207–217.
30.
ChenMLYiLJinX, et al.
Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy2013;
9: 2033–2045.
31.
ChengALuYHuangQ, et al.
Attenuating oxygen-glucose deprivation-caused autophagosome accumulation may be involved in sevoflurane postconditioning-induced protection in human neuron-like cells. Eur J Pharmacol2019;
849: 84–95.
32.
VionACKheloufiMHammouteneA, et al.
Autophagy is required for endothelial cell alignment and atheroprotection under physiological blood flow. Proc Natl Acad Sci U S A2017;
114: E8675–e8684.
33.
DomiganCKWarrenCMAntanesianV, et al.
Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy. J Cell Sci2015;
128: 2236–2248.
34.
NemotoEMYonasHChangY.Stages and thresholds of hemodynamic failure. Stroke2003;
34: 2–3.
35.
ParkGHShinHSChoiES, et al.
Cranial burr hole with erythropoietin administration induces reverse arteriogenesis from the enriched extracranium. Neurobiol Dis2019;
132: 104538.
36.
HongJMChoiMHParkGH, et al.
Transdural revascularization by multiple burrhole after erythropoietin in stroke patients with cerebral hypoperfusion: a randomized controlled trial. Stroke2022;
53: 2739–2748.
37.
KhooCPMicklemKWattSM.A comparison of methods for quantifying angiogenesis in the matrigel assay in vitro. Tissue Eng Part C Methods2011;
17: 895–906.
38.
HamauchiSShichinoheHUchinoH, et al.
Cellular functions and gene and protein expression profiles in endothelial cells derived from moyamoya Disease-Specific iPS cells. PLoS One2016;
11: e0163561.
39.
SunSJZhangJJLiZW, et al.
Histopathological features of middle cerebral artery and superficial temporal artery from patients with moyamoya disease and enlightenments on clinical treatment. J Huazhong Univ Sci Technolog Med Sci2016;
36: 871–875.
40.
TokairinKHamauchiSItoM, et al.
Vascular smooth muscle cell derived from IPS cell of moyamoya disease – comparative characterization with endothelial cell transcriptome. J Stroke Cerebrovasc Dis2020;
29: 105305.
41.
GotoAGotoMTerauchiY, et al.
Association between severe hypoglycemia and cardiovascular disease risk in Japanese patients with type 2 diabetes. J Am Heart Assoc2016;
5: e002875.
42.
JoyNGTateDBYounkLM, et al.
Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans. Diabetes2015;
64: 2571–2580.
43.
DesouzaCSalazarHCheongB, et al.
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care2003;
26: 1485–1489.
44.
MatsudaYMineharuYKimuraM, et al.
RNF213 p.R4810K variant and intracranial arterial stenosis or occlusion in relatives of patients with moyamoya disease. J Stroke Cerebrovasc Dis2017;
26: 1841–1847.
45.
CelermajerDSSorensenKEGoochVM, et al.
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet1992;
340: 1111–1115.
46.
HillJMZalosGHalcoxJP, et al.
Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med2003;
348: 593–600.
47.
BangOYFujimuraMKimSK.The pathophysiology of moyamoya disease: an update. J Stroke2016;
18: 12–20.
48.
Santos-GarcíaDBlancoMSerenaJ, et al.
Brachial arterial flow mediated dilation in acute ischemic stroke. Eur J Neurol2009;
16: 684–690.
49.
Santos-GarcíaDBlancoMSerenaJ, et al.
Impaired brachial flow-mediated dilation is a predictor of a new-onset vascular event after stroke. Cerebrovasc Dis2011;
32: 155–162.
50.
KobayashiHMatsudaYHitomiT, et al.
Biochemical and functional characterization of RNF213 (mysterin) R4810K, a susceptibility mutation of moyamoya disease, in angiogenesis in vitro and in vivo. J Am Heart Assoc2015;
4: 20150630.
51.
OttenEGWernerECrespillo-CasadoA, et al.
Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature2021;
594: 111–116.
52.
LumkwanaDDu ToitAKinnearC, et al.
Autophagic flux control in neurodegeneration: progress and precision targeting – where do we stand?Prog Neurobiol2017;
153: 64–85.
53.
HuXLuZYuS, et al.
CERKL regulates autophagy via the NAD-dependent deacetylase SIRT1. Autophagy2019;
15: 453–465.
54.
MameliEMartelloACaporaliA.Autophagy at the interface of endothelial cell homeostasis and vascular disease. Febs j2022;
289: 2976–2991.
55.
LiHGaoAFengD, et al.
Evaluation of the protective potential of brain microvascular endothelial cell autophagy on blood-brain barrier integrity during experimental cerebral ischemia-reperfusion injury. Transl Stroke Res2014;
5: 618–626.
56.
LiuSSarkarCDinizoM, et al.
Disrupted autophagy after spinal cord injury is associated with ER stress and neuronal cell death. Cell Death Dis2015;
6: e1582.
57.
HedyaSASafarMMBahgatAK.Cilostazol mediated Nurr1 and autophagy enhancement: Neuroprotective activity in rat rotenone PD model. Mol Neurobiol2018;
55: 7579–7587.
58.
LeeHRShinHKParkSY, et al.
Cilostazol upregulates autophagy via SIRT1 activation: reducing amyloid-β peptide and APP-CTFβ levels in neuronal cells. PLoS One2015;
10: e0134486.
59.
ParkSYLeeHRLeeWS, et al.
Cilostazol modulates autophagic degradation of β-amyloid peptide via SIRT1-coupled LKB1/AMPKα signaling in neuronal cells. PLoS One2016;
11: e0160620.
